Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 5Carcinoma, Non-Small-Cell Lung 5Squamous Cell Carcinoma of Head and Neck 4Rectal Neoplasms 4Neoplasms 4Head and Neck Neoplasms 4Colorectal Neoplasms 4Stomach Neoplasms 3Glioma 3Esophageal Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Brain Neoplasms 3Astrocytoma 3Sarcoma 2Pancreatic Neoplasms 2Osteosarcoma 2Lung Neoplasms 2Carcinoma, Squamous Cell 2Wilms Tumor 1Urinary Bladder Neoplasms 1Skin Neoplasms 1Sinonasal Squamous Cell Carcinoma 1Rhabdomyosarcoma 1Recurrence 1Radiation Injuries 1Prostatic Neoplasms 1Prostate Adenocarcinoma 1Postoperative Complications 1Pilonidal Sinus 1

Interventions

cemiplimab 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Cisplatin 1Chemoradiotherapy 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sinonasal Squamous Cell Carcinoma × Surgical Procedures, Operative × 90 days × Clear all
NCT07281417 2026-05-22

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
108 enrolled

Sinonasal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡